-
Document de presse | 2021.11.18
Covid-19: Systematic review of the clinical and immunological efficacy of vaccines in immunocompromised people
The team from the Cochin-Pasteur Clinical Investigation Center of Vaccinology at Cochin AP-HP Hospital, Inserm and the University of Paris, coordinated by Prof. Odile Launay, carried out a systematic review of the literature on immunogenicity and efficacy of Covid-19 vaccines in immunocompromised individuals. It concluded that there is a risk of low immunogenicity of Covid-19 vaccines among...
-
Document de presse | 2021.07.01
Modelling study of benefits and risks associated with the COVID-19 vaccine Vaxzevria
On April 7, 2021, the European Medical Agency (EMA) concluded that thrombosis in combination with thrombocytopenia has been identified as a likely adverse event following vaccination with the COVID-19 vaccine Vaxzevria. Researchers from the Mathematical Modelling of Infectious Diseases Unit at the Institut Pasteur used a mathematical model to assess its benefits and risks in...
-
News | 2019.09.27
Rabies: a shorter, cheaper vaccination schedule following a suspected rabid dog bite
A study by teams from the Institut Pasteur du Cambodge and the Institut Pasteur in Paris confirms the efficacy of the new post-exposure rabies vaccination schedule developed in the Institut Pasteur International Network and adopted by the World Health Organization (WHO). Since 2018, WHO has recommended post-exposure vaccination for rabies, immediately after a bite by a suspected rabid...
-
News | 2024.10.08
Can lymphoid organs-on-chip be used to evaluate the effectiveness of booster vaccines?
Researchers at the Institut Pasteur, a Carnot-labeled institute, have developed an innovative technology: "lymphoid organ-on-chip" devices that are capable of simulating the human immune system’s response to booster vaccines. This breakthrough could provide a versatile preclinical system to evaluate vaccine candidates in the face of rapidly evolving pandemics such as that caused by the SARS-CoV-2...
-
News | 2017.10.20
Malaria: Plasmodium falciparum protein MSP4 is a potential target for a vaccine
According to WHO estimates, in 2015, there were 212 million cases of malaria and 429,000 deaths worldwide. Sub-Saharan Africa alone accounts for 90% of cases and 92% of deaths. In this region, the parasite Plasmodium falciparum, responsible for the majority of deaths, is the most common/frequent. Since 2010, integrated control measures (insecticide-treated mosquito nets, insecticide sprays, etc...
-
Article | 2020.06.16
Generation of animal models sensitive to SARS-CoV-2 to test vaccines or drugs
Aim: Rapid development of animal models is of utmost importance to test the efficacy of vaccines and drug against COVID-19. The aim of this research project is to propose models whose cells express the human ACE2 proteins (huACE2) so that they are sensitive to SARS-CoV-2. The ACE2 protein is the gateway for the virus to enter cells. Researchers are proposing to use adenoviruses and...
-
Document de presse | 2004.02.19
Rift Valley Fever: New Therapeutic Targets and a Candidate Vaccine in Trials
Research teams from INSERM and the Institut Pasteur have just discovered the virulence mechanism of the Rift Valley Fever virus. This virus, often fatal in humans, regularly decimates herds of livestock in Africa. Understanding the interactions between the host and this virus should make it possible to identify new therapeutic targets against Rift Valley Fever. This research, published in the...
-
Document de presse | 2015.01.13
Identification of an Achilles heel in the dengue virus gives new hope for vaccine development
In association with Imperial College London, scientists at the Institut Pasteur and CNRS have identified a vulnerable site on the surface of the dengue virus which is targeted by the only broadly neutralizing antibodies identified to date. This discovery offers a new target for the development of a vaccine to combat all four types of dengue virus currently in circulation. These results were...
-
News | 2017.01.12
Yellow fever: using modeling to optimize the use of vaccine stocks
In December 2015 a yellow fever epidemic broke out in Angola, subsequently giving rise to 7,300 suspected cases and nearly 400 deaths. A group of scientists from Oxford University and the Institut Pasteur conducted research into the geographical spread of this epidemic, with the aim of containing this outbreak and optimizing the use of the limited available vaccine stock.According to the World...
-
Article | 2020.07.07
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine